178 related articles for article (PubMed ID: 34315295)
41. Rituximab in Treatment of Children with Refractory Vasculitis and Systemic Lupus Erythematosus - Single Center Experience in Croatia.
Sršen S; Frković M; Malčić I; Jelušić M
Acta Dermatovenerol Croat; 2020 Aug; 28(2):63-69. PubMed ID: 32876030
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of Whole-Blood Exchange Transfusion in Refractory Severe Autoimmune Haemolytic Anaemia Secondary to Systemic Lupus Erythematosus: A Real-World Observational Retrospective Study.
Jiang Y; Zhao HJ; Luo H; Li BJ; Zhang ZM; Zhao LD; Zuo XX
Front Immunol; 2022; 13():861719. PubMed ID: 35757744
[TBL] [Abstract][Full Text] [Related]
43. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.
McCarthy EM; Sutton E; Nesbit S; White J; Parker B; Jayne D; Griffiths B; Isenberg DA; Rahman A; Gordon C; D'Cruz DP; Rhodes B; Lanyon P; Vital EM; Yee CS; Edwards CJ; Teh LS; Akil M; McHugh NJ; Zoma A; Bruce IN;
Rheumatology (Oxford); 2018 Mar; 57(3):470-479. PubMed ID: 29216396
[TBL] [Abstract][Full Text] [Related]
44. BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months case-control study.
Kalashnikova E; Isupova E; Gaidar E; Sorokina L; Kaneva M; Masalova V; Dubko M; Kornishina T; Lubimova N; Kuchinskaya E; Chikova I; Raupov R; Kalashnikova O; Kostik M
World J Clin Pediatr; 2024 Mar; 13(1):89049. PubMed ID: 38596443
[TBL] [Abstract][Full Text] [Related]
45. Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein).
Maritati F; Fenoglio R; Pillebout E; Emmi G; Urban ML; Rocco R; Nicastro M; Incerti M; Goldoni M; Trivioli G; Silvestri E; Mohammad AJ; Jayne D; Eriksson P; Segelmark M; Novikov P; Harris H; Roccatello D; Vaglio A
Arthritis Rheumatol; 2018 Jan; 70(1):109-114. PubMed ID: 28973844
[TBL] [Abstract][Full Text] [Related]
46. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
[TBL] [Abstract][Full Text] [Related]
47. Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.
Chavarot N; Verhelst D; Pardon A; Caudwell V; Mercadal L; Sacchi A; Leonardi C; Le Guern V; Karras A; Daugas E;
Medicine (Baltimore); 2017 Jul; 96(27):e7429. PubMed ID: 28682905
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.
Iwata S; Saito K; Hirata S; Ohkubo N; Nakayamada S; Nakano K; Hanami K; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Yoshinari H; Tanaka Y
Lupus; 2018 Apr; 27(5):802-811. PubMed ID: 29308726
[TBL] [Abstract][Full Text] [Related]
49. Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
Lekpa FK; Ngahane BHM; Njonnou SRS; Fouda H; Halle MP; Njankouo YM; Dzudie A; Choukem SP; Luma HN
Pan Afr Med J; 2021; 38():372. PubMed ID: 34367451
[TBL] [Abstract][Full Text] [Related]
50. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus.
Hickman RA; Hira-Kazal R; Yee CS; Toescu V; Gordon C
Clin Rheumatol; 2015 Feb; 34(2):263-71. PubMed ID: 25564308
[TBL] [Abstract][Full Text] [Related]
51. Successful early rituximab treatment in a case of systemic lupus erythematosus with potentially fatal diffuse alveolar hemorrhage.
Na JO; Chang SH; Seo KH; Choi JS; Lee HS; Lyu JW; Nah SS
Respiration; 2015; 89(1):62-5. PubMed ID: 25531296
[TBL] [Abstract][Full Text] [Related]
52. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
Podolskaya A; Stadermann M; Pilkington C; Marks SD; Tullus K
Arch Dis Child; 2008 May; 93(5):401-6. PubMed ID: 18039744
[TBL] [Abstract][Full Text] [Related]
53. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.
Hofmann SC; Leandro MJ; Morris SD; Isenberg DA
Lupus; 2013 Aug; 22(9):932-9. PubMed ID: 23894047
[TBL] [Abstract][Full Text] [Related]
54. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
55. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
Galarza C; Valencia D; Tobón GJ; Zurita L; Mantilla RD; Pineda-Tamayo R; Rojas-Villarraga A; Rueda JC; Anaya JM
Clin Rev Allergy Immunol; 2008 Feb; 34(1):124-8. PubMed ID: 18270866
[TBL] [Abstract][Full Text] [Related]
56. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
[TBL] [Abstract][Full Text] [Related]
57. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
58. Resorption of immune deposits in membranous lupus nephritis following rituximab vs conventional immunosuppressive treatment.
Zickert A; Lannfelt K; Schmidt Mende J; Sundelin B; Gunnarsson I
Rheumatology (Oxford); 2021 Jul; 60(7):3443-3450. PubMed ID: 33367774
[TBL] [Abstract][Full Text] [Related]
59. Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus.
Bang SY; Lee CK; Kang YM; Kim HA; Suh CH; Chung WT; Park YB; Choe JY; Kim TJ; Park YW; Yoo DH; Bae SC; Lee HS
Autoimmune Dis; 2012; 2012():565039. PubMed ID: 23304457
[TBL] [Abstract][Full Text] [Related]
60. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.
Pirone C; Mendoza-Pinto C; van der Windt DA; Parker B; O Sullivan M; Bruce IN
Semin Arthritis Rheum; 2017 Dec; 47(3):384-396. PubMed ID: 28602359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
